Corinne Wessner

Mrs. Corinne Wessner

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Radiology
Verified
Journal Article
Closed access
John EisenbreyJohn Eisenbrey
John Eisenbrey
FFFlemming Forsberg
Flemming Forsberg
CWCorinne E. Wessner
Corinne E. Wessner
LDLauren J. Delaney
Lauren J. Delaney
KBKristen Bradigan
Kristen Bradigan
CSColette M. Shaw
Colette M. Shaw
Combined US-triggered microbubble destruction and hepatocellular carcinoma radioembolization showed improved treatment response compared with radioembolization alone and no changes in vital signs o... Background US contrast agents are gas-filled microbubbles (MBs) that can be locally destroyed by using external US. Among other bioeffects, US-triggered MB destruction, also known as UTMD, has been...

17 November 2020 in Radiology
Verified
Journal Article
Closed access
IGIpshita Gupta
Ipshita Gupta
John EisenbreyJohn Eisenbrey
John Eisenbrey
PMPriscilla Machado
Priscilla Machado
MSMaria Stanczak
Maria Stanczak
CWCorinne E. Wessner
Corinne E. Wessner
FFFlemming Forsberg
Flemming Forsberg
Subharmonic-aided pressure estimation measurements correlate well with hepatic venous pressure gradient measurements and allow identification of participants with portal hypertension and those at e... Background The current standard for assessing the severity of portal hypertension is the invasive acquisition of hepatic venous pressure gradient (HVPG). A noninvasive US-based technique called sub...

20 February 2023 in Journal of Ultrasound in Medicine
Verified
Journal Article
Closed access
ATAylin Tahmasebi
Aylin Tahmasebi
SWShuo Wang
Shuo Wang
CWCorinne E. Wessner
Corinne E. Wessner
TVTrang Vu
Trang Vu
JLJi‐Bin Liu
Ji‐Bin Liu
John EisenbreyJohn Eisenbrey
John Eisenbrey

1 October 2023 in Radiology
Verified
Journal Article
Closed access
ESEsika Savsani
Esika Savsani
CSColette M. Shaw
Colette M. Shaw
FFFlemming Forsberg
Flemming Forsberg
CWCorinne E. Wessner
Corinne E. Wessner
ALAndrej Lyshchik
Andrej Lyshchik
John EisenbreyJohn Eisenbrey
John Eisenbrey
Background Contrast-enhanced (CE) US has been studied for use in the detection of residual viable hepatocellular carcinoma (HCC) after locoregional therapy, but multicenter data are lacking. Purpose To compare two-dimensional (2D) and three-dimensional (3D) CE US diagnostic performance with that of CE MRI or CT, the current clinical standard, in the detection of residual viable HCC after transarterial chemoembolization (TACE) in a prospective multicenter trial. Materials and Methods Participants aged at least 21 years with US-visible HCC scheduled for TACE were consecutively enrolled at one of three participating academic medical centers from May 2016 to March 2022. Each underwent baseline 2D and 3D CE US before TACE, 2D and 3D CE US 1-2 weeks and/or 4-6 weeks after TACE, and CE MRI or CT 4-6 weeks after TACE. CE US and CE MRI or CT were evaluated by three fellowship-trained radiologists for the presence or absence of viable tumors and were compared with reference standards of pathology (18%), angiography on re-treatment after identification of residual disease at 1-2-month follow-up imaging (31%), 4-8-month CE MRI or CT (42%), or short-term (approximately 1-2 months) CE MRI or CT if clinically decompensated and estimated viability was greater than 50% at imaging (9%). Diagnostic performance criteria, including sensitivity and specificity, were obtained for each modality and time point with generalized estimating equation analysis. Results A total of 132 participants were included (mean age, 64 years ± 7 [SD], 87 male). Sensitivity of 2D CE US 4-6 weeks after TACE was 91% (95% CI: 84, 95), which was higher than that of CE MRI or CT (68%; 95% CI: 58, 76; P < .001). Sensitivity of 3D CE US 4-6 weeks after TACE was 89% (95% CI: 81, 94), which was higher than that of CE MRI or CT (P < .001), with no evidence of a difference from 2D CE US (P = .22). CE MRI or CT had 85% (95% CI: 76, 91) specificity, higher than that of 4-6-week 2D and 3D CE US (70% [95% CI: 56, 80] and 67% [95% CI: 53, 78], respectively; P = .046 and P = .023, respectively). No evidence of differences in any diagnostic criteria were observed between 1-2-week and 4-6-week 2D CE US (P > .21). Conclusion The 2D and 3D CE US examinations 4-6 weeks after TACE revealed higher sensitivity in the detection of residual HCC than CE MRI or CT, albeit with lower specificity. Importantly, CE US performance was independent of follow-up time. Clinical trial registration no. NCT02764801 © RSNA, 2023 Supplemental material is available for this article.

1 July 2023 in Endoscopic Ultrasound
Verified
Journal Article
Open access
JLJi-Bin Liu
Ji-Bin Liu
PMPriscilla Machado
Priscilla Machado
John EisenbreyJohn Eisenbrey
John Eisenbrey
SGSriharsha Gummadi
Sriharsha Gummadi
FFFlemming Forsberg
Flemming Forsberg
DLDavid Loren
David Loren
Objectives: The objective of this pilot study was to compare the performance of contrast-enhanced EUS (CE-EUS)–guided fine-needle aspiration (FNA) with EUS-FNA for lymph node (LN) staging in esophageal cancer. Methods: Thirty-seven subjects with esophageal cancer undergoing EUS staging were enrolled, and 30 completed this institutional review board–approved study. A Prosound F75 US system (Hitachi Medical Systems, Tokyo, Japan) with harmonic contrast imaging software and GF-UCT180 curvilinear endoscope (Olympus, Tokyo, Japan) was utilized. All LNs identified by standard EUS were first noted. Sonazoid (dose: 1 mL; GE Healthcare, Oslo, Norway) was administered peritumorally, and all enhanced LNs were recorded. Fine-needle aspiration was performed on LNs considered suspicious by EUS alone, as well as LNs enhanced on CE-EUS. Performance of each modality was compared using FNA cytology as reference standard. Results: A total of 132 LNs were detected with EUS, of which 59 showed enhancement on CE-EUS. Fifty-three LNs underwent FNA, and 22 LNs were determined to be malignant. Among the latter, 10 were considered suspicious by EUS, whereas the other 12 LNs underwent FNA only because of CE-EUS enhancement. Contrast-enhanced EUS showed enhancement in 19 of the 22 malignant LNs. The rate of metastatic node identification from EUS was 45% (10/22), and it was 86% (19/22; P = 0.008) for CE-EUS. Eight subjects (8/30 [27% of study total]) had nodal status upgraded by the addition of CE-EUS, which influenced LN staging and clinical management. Conclusions: Fine-needle aspiration of LNs identified by CE-EUS may increase metastasis positive rate by ruling out LNs not associated with the tumor drainage pattern. In addition, CE-EUS seems to identify more metastatic LNs that would not be biopsied under the standard EUS criteria.

4 January 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
PMPriscilla Machado
Priscilla Machado
IGIpshita Gupta
Ipshita Gupta
SGSriharsha Gummadi
Sriharsha Gummadi
MSMaria Stanczak
Maria Stanczak
CWCorinne E. Wessner
Corinne E. Wessner
FFFlemming Forsberg
Flemming Forsberg